Anixa Bio down 16% on extended timeline for CAR T candidateAnixa Bio在延长的T车候选时间上下降了16%

原标题：Anixa Bio down 16% on extended timeline for CAR T candidateAnixa Bio在延长的T车候选时间上下降了16% 来源：seekingalpha

Thinly traded nano cap Anixa Biosciences (ANIX-16.4%) is down more on than triple normal volume, albeit on turnover of only 165K shares, in apparent response to a longer development timeline for a CAR T therapy it is developing with Moffitt Cancer Center designed to express follicle stimulating hormone (FSH) for the potential treatment of FSH receptor-expressing cancers.

Recent experiments showed that additional engineering may enable the transformed cells to significantly increase FSH expression so the decision has been made to pursue the opportunity, an effort expected to take as long as a year. Consequently, an IND will not be filed until late 2020 with clinical trials to commence in 2021.

See all stocks on the move »

Now read:BioLineRx (BLRX) Presents At ESMO Immuno-Oncology Congress 2019 - Slideshow »

Try Seeking Alpha PREMIUM for unlimited analysis on ANIX

尽管成交量仅为165 K股，但Anixa生物科学指数(ANIX-16.4%)的跌幅超过正常成交量的三倍，这显然是对它与Moffitt癌症中心(Moffitt CancerCenter)共同开发的、旨在表达卵泡刺激素(FSH)以潜在治疗FSH受体的癌症而开发的一种更长的发展时间的反应。

最近的实验表明，额外的工程可能会使转化后的细胞显著增加FSH的表达，因此已经做出了寻找机会的决定，这一努力预计需要一年的时间。因此，IND要到2020年末才会提交，临床试验将于2021年开始。

看到所有的股票在移动？

现在阅读：BioLineRx(BLRX)在ESMO免疫学大会上的介绍

为ANIX无限分析寻找阿尔法溢价